Gastric Cancer Treatment Market, By Treatment (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa - Trends, Analysis and Forecast till 2034

The gastric cancer treatment market is expected to increase at a compound annual growth rate (CAGR) of 13.7% from its 2024 valuation of US$5.4 billion to US$19.4 billion by 2034.

The term "gastric cancer" or "stomach cancer" refers to the development of malignant cells in the stomach lining. For instance, several malignancies that metastasize in various cell types have been observed: adenocarcinoma in cells that produce mucus, gastrointestinal neuroendocrine tumors in neuroendocrine cells, and gastroesophageal junction adenocarcinoma in the region where the esophagus enters the stomach cardia.

The market for gastric cancer treatments is expected to rise as a result of the rise in stomach cancer cases reported worldwide. Furthermore, it is anticipated that the number of cases of stomach cancer will increase over the coming years, which will raise the need for effective treatments. There has been a rise in the consumption of highly processed foods, sugary drinks, smoking, genetic mutations, alcohol, and family history of cancer, the reasons behind gastric cancer. Sedentary lifestyles and inconsistent eating patterns are causing devastating illnesses such as gastric cancer.